Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 17,392 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 17,392 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total transaction of $315,838.72. Following the sale, the chief operating officer owned 205,141 shares in the company, valued at approximately $3,725,360.56. This trade represents a 7.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, January 22nd, Ryan Cohlhepp sold 3,828 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.10, for a total value of $69,286.80.
• On Thursday, January 15th, Ryan Cohlhepp sold 149 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.02, for a total value of $2,684.98.
• On Monday, December 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.68, for a total value of $233,500.00.

Bicara Therapeutics Stock Down 0.2%

NASDAQ:BCAX traded down $0.04 during mid-day trading on Thursday, reaching $18.50. The company’s stock had a trading volume of 950,200 shares, compared to its average volume of 516,872. The company’s fifty day simple moving average is $16.43 and its two-hundred day simple moving average is $15.70. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $19.71.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Citigroup initiated coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating for the company. Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, January 13th. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.33.

Institutional Investors Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of BCAX. Deutsche Bank AG boosted its holdings in Bicara Therapeutics by 0.9% during the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock valued at $2,165,000 after purchasing an additional 1,171 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after acquiring an additional 1,474 shares during the last quarter. Mariner LLC boosted its stake in Bicara Therapeutics by 3.0% in the fourth quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after purchasing an additional 1,902 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Bicara Therapeutics by 13.2% in the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after buying an additional 1,962 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.